RxSight, Inc. To Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
RxSight (NASDAQ:RXST) will report fourth quarter and full year 2025 financial results after market close on February 25, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
RxSight (NASDAQ:RXST) will report fourth quarter and full year 2025 financial results after market close on February 25, 2026. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results and take questions.
Dial-in numbers, conference code 3406720, a live listen-only webcast and an archived recording will be available on the company’s investor relations website.
Details
News Market Reaction – RXST
On Feb 12, the first trading day after this news, RXST closed 2.86% below the previous close.
Data tracked by StockTitan Argus for the Feb 12 session.
Key Figures
- Earnings release date
- February 25, 2026
- Q4 and full year 2025 results release after market close
- Conference call time PT
- 1:30 p.m. Pacific Time
- Scheduled start time for Q4/FY 2025 earnings call
- Conference call time ET
- 4:30 p.m. Eastern Time
- Scheduled start time for Q4/FY 2025 earnings call
- US toll-free dial-in
- (800) 715-9871
- Participant dial-in number for the earnings call
- Alternate dial-in
- (646) 307-1963
- Alternate participant dial-in number for the earnings call
- Conference code
- 3406720
- Access code required to join the earnings conference call
Historical Context
-
JP Morgan Healthcare presentation and webcast access details.
-
Announcement of CFO transition and consulting arrangement.
-
Piper Sandler conference presentation scheduling and webcast info.
-
Q3 2025 results with lower revenue and wider loss but higher margins.
-
Announcement of Q3 2025 earnings release date and call details.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
ophthalmic medical
cataract surgery medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
ALISO VIEJO, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, will report financial results for the fourth quarter and full year 2025 after the market close on Wednesday, February 25, 2026. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963, and enter the conference code: 3406720. The call will also be broadcast live in listen-only mode via a link on the company’s investor relations website at https://investors.rxsight.com/. An archived recording of the call will be available through the same link shortly after its completion.
About RxSight, Inc.
RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®/LAL+®, collectively the “LAL”), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.
Investor Relations Contact:
Oliver Moravcevic
VP, Investor Relations
omoravcevic@rxsight.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.